Replies to post #27646 on MindMaze Therapeutics Holding (RLFTF)

[Uncle Gee Gee]

Ahhh... "vaso dilating" is the term I couldn't recall. Yep... that's what Javitt was describing.

[arain1234]

Can you please provide a reference?

[PennyWorld]

Nice recap Nelskof... this makes perfect sense to me!! RLF-100 targets the lungs and the VPAC1 receptor (which is tied to COVID19). The other failed drug (from PhaseBIO) targets the blood vessels (VPAC2 receptor) and treating high blood pressure. Two different drugs to treat two different issues.

With the dropout of PhaseBIO, we now have less competition on the VIP front.

Even if one has trouble understanding the technical jargon, the way I'm viewing this is there is hands-on empirical evidence that RFL-100 works on living human beings. We can't forget the 21 patients and the 19 that survived!! The proof is in the pudding.

IMO, RLF-100 will be around as a key therapeutic tool for many years to come (IV and inhaled).

[Inelgr]

What is RLF-100™’s mode-of-action?
RLF-100TM is a synthetic Vasoactive Intestinal Peptide (VIP) that has a multimodal mechanism of action. It binds to Type 2 alveolar cells (found in the lungs), resulting in a significant modulation of the immune cell response (macrophages, CD4-T cells and tolerogenic dendritic cells) mediated by activation of the VPAC1 and VPAc2 receptors. RLF-100TM thus plays an anti-inflammatory and immunomodulatory role vis-à-vis the immune cells; {VPAC1} has vasodilatory and inotropic effects through the vascular system;{VPAC2} and helps to maintain the bronchial system by upregulating the production of surfactant in the lungs, preventing cell death.

https://relieftherapeutics.com/investor-relations